- Home
- MIRM vs INTR Comparison
MIRM vs INTR Comparison
Compare MIRM & INTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- INTR
- Stock Information
- Founded
- MIRM 2018
- INTR 1994
- Country
- MIRM United States
- INTR Brazil
- Employees
- MIRM N/A
- INTR N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- INTR
- Sector
- MIRM Health Care
- INTR
- Exchange
- MIRM Nasdaq
- INTR Nasdaq
- Market Cap
- MIRM 2.5B
- INTR 2.1B
- IPO Year
- MIRM 2019
- INTR N/A
- Fundamental
- Price
- MIRM $52.45
- INTR $5.21
- Analyst Decision
- MIRM Strong Buy
- INTR Strong Buy
- Analyst Count
- MIRM 11
- INTR 3
- Target Price
- MIRM $57.00
- INTR $7.30
- AVG Volume (30 Days)
- MIRM 504.4K
- INTR 2.2M
- Earning Date
- MIRM 02-26-2025
- INTR 02-06-2025
- Dividend Yield
- MIRM N/A
- INTR 1.55%
- EPS Growth
- MIRM N/A
- INTR 176.00
- EPS
- MIRM N/A
- INTR 0.33
- Revenue
- MIRM $307,028,000.00
- INTR $743,862,312.00
- Revenue This Year
- MIRM $83.04
- INTR N/A
- Revenue Next Year
- MIRM $27.22
- INTR $17.41
- P/E Ratio
- MIRM N/A
- INTR $15.42
- Revenue Growth
- MIRM 112.14
- INTR 43.28
- 52 Week Low
- MIRM $23.14
- INTR $3.88
- 52 Week High
- MIRM $54.23
- INTR $7.84
- Technical
- Relative Strength Index (RSI)
- MIRM 64.07
- INTR 51.92
- Support Level
- MIRM $51.02
- INTR $5.05
- Resistance Level
- MIRM $53.76
- INTR $5.63
- Average True Range (ATR)
- MIRM 2.04
- INTR 0.23
- MACD
- MIRM 0.03
- INTR -0.02
- Stochastic Oscillator
- MIRM 73.31
- INTR 27.59
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop & Commerce Plus. It generates maximum revenue from the Banking & Spending.